Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

Provided By PR Newswire

Last update: Jul 13, 2023

Sickle Cell Disease Treatment Commercially Available in Five GCC Countries

TORRANCE, Calif., July 13, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari® (L-glutamine oral powder) in the country to treat sickle cell disease in patients five years of age and older.